Skip to content
MarketScale
‹ Back to IndustriesSciences

Can Scientists Use ChatGPT for Scientific Research?

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · Ai ToolsArtificial IntelligenceChatgptResearch Methods
Share

Key takeaways

01

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers.

02

The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient….

Get featured

Want MarketScale to feature Sciences?

Book a 15-minute demo and we'll map your Sciences expertise to the content buyers are searching for.

Book a demo

In December 2022, University of Colorado School of Medicine’s Casey Greene and Perelman School of Medicine’s Milton Pividori performed an experiment using ChatGPT to improve three research papers. The focus of the experiment was to see whether OpenAI’s language models were robust enough to supplement academic papers to make writing and revising manuscripts more efficient. Surprisingly for the academic community, the experiment proved successful, with their research finding that OpenAI’s models “can capture the concepts in the scholarly text and produce high-quality revisions that improve clarity.” More readable and accessible academic manuscripts sounds like a win for everyone involved, but how else can AI-supported chatbots support the academic community? Greene and Pividori’s research leaves many wondering whether scientists dealing in rigorous and highly-technical subjects can leverage ChatGPT for scientific research from start to finish.

ChatGPT was launched in November 2022 and got over 1 million users within the first week of its launch; OpenAI’s tool is clearly highly popular and gaining mainstream appeal, validating new use cases every week. The tool can perform complex tasks that save loads of time and energy, and can produce text like poetry, prose, computer code, and even topical research ideas. However, it’s not a perfect tool by any stretch. High level thought leaders in the tech community, including Steve Wozniak, warn that ChatGPT’s text generation can be riddled with errors. Obviously, anything of academic quality can’t have erroneous revisions applied.

Scientists use various types of research methods to gather information to develop their hypotheses and supplement academic texts, including digging for sources, conducting hypothetical scientific models to prove their research, running surveys for new data, and more. With ChatGPT Plus hot on our heels, should scientists start to use ChatGPT for scientific research? How confident can they be in its efficacy? Justin Bean, author of What Could Go Right and an experienced sustainability and smart city strategist working with Fortune 500s and cutting-edge start-ups, weighs in with his take. Bean is highly familiar with the research process; he spent many years as a clean tech and green energy consultant, where he conducted layered and rigorous research of financial data, venture capital investments, trend reports and more.

Justin’s Thoughts:

“So, if Siri gave everyone a digital assistant, ChatGPT gives everyone a digital intern. This means it can do way more work for us and including in science. So, a lot of the work in science and data analysis is all about gathering and blending and cleaning and compiling data, and about making interpretations that lead to some kind of insight, which they can then take and do science with.

Now because of ChatGPT, a lot of that early stage can be done by an AI and that’ll free up scientists to have a lot more time doing the science. But not just that, it’s going to free a lot of people up to be able to do science who aren’t conventional scientists and people who don’t have PhDs. This is because it’s going to do a lot of that initial work and be able to explain it in everyday layman’s terms for you and me to be able to do the science.

And I think that’s going to democratize a lot of inventions and a lot of science as innovators from around the world and different perspectives, it will bring their perspectives to science and leverage the information they can get through chatGPT. Now, as this develops, all these AIs are going to become more and more specialized.

So you may have a specialized artificial intelligence for cancer science and detection, and another one for weather science or climate science. Many different ones will proliferate. In addition, we’re going to have autonomous economic agents that will take that information and go out and acquire materials or goods or contracts for us just to make a lot of that process a lot easier and make us all more effective.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512